Rein Therapeutics, Inc. - RNTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Jul 14, 2026 | SCHEDULE 13G/A | Voss Value Master Fund, LP | 1.2% | 1,000,000 | View |
| Jul 14, 2026 | SCHEDULE 13G/A | Voss Value-Oriented Special Situations Fund, LP | 0.6% | 500,000 | View |
| Jul 14, 2026 | SCHEDULE 13G/A | Voss Advisors GP, LLC | 1.8% | 1,500,000 | View |
| Jul 14, 2026 | SCHEDULE 13G/A | Voss Capital, LP | 6.6% | 5,656,957 | View |
| Jul 14, 2026 | SCHEDULE 13G/A | Cocke Travis W. | 6.6% | 5,656,957 | View |
| May 08, 2026 | SCHEDULE 13G/A | Bios Fund I, LP | 2.06% | 1,610,565 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS CAPITAL MANAGEMENT, LP | 9.99% | 7,797,502 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS FUND II, LP | 0.51% | 398,767 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS FUND II QP, LP | 1.67% | 1,302,654 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS FUND II NT, LP | 0.22% | 173,217 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS EQUITY PARTNERS, LP | 0.0% | 1,249 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS CLINICAL OPPORTUNITY FUND, LP | 2.96% | 2,313,797 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS FUND III QP, LP | 1.71% | 1,332,850 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS FUND III NT, LP | 0.27% | 214,346 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS ADVISORS GP, LLC | 9.99% | 7,797,502 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS FUND III, LP | 0.26% | 204,092 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS EQUITY COF, LP | 2.24% | 1,751,288 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS EQUITY PARTNERS II, LP | 2.4% | 1,874,638 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS EQUITY PARTNERS III, LP | 2.24% | 1,751,288 | View |
| May 08, 2026 | SCHEDULE 13G/A | CAVU ADVISORS, LLC | 9.99% | 7,797,502 | View |
| May 08, 2026 | SCHEDULE 13G/A | CAVU MANAGEMENT, LP | 9.99% | 7,797,502 | View |
| May 08, 2026 | SCHEDULE 13G/A | LESLIE W. KREIS | 9.99% | 7,797,502 | View |
| May 08, 2026 | SCHEDULE 13G/A | AARON G.L. FLETCHER | 9.99% | 7,797,502 | View |
| May 08, 2026 | SCHEDULE 13G/A | BIOS FUND I QP, LP | 1.21% | 941,887 | View |
| May 08, 2026 | SCHEDULE 13G/A | Bios LTI Co-Invest III QP, LP | 5.51% | 4,303,099 | View |
| May 08, 2026 | SCHEDULE 13G/A | Bios LTI Co-Invest III, LP | 5.38% | 4,198,037 | View |
| May 08, 2026 | SCHEDULE 13G/A | Bios LTI SPV II, LP | 1.91% | 1,487,007 | View |
| May 08, 2026 | SCHEDULE 13G/A | Bios 2026 Co-Invest, LP | 1.28% | 1,000,000 | View |
| May 08, 2026 | SCHEDULE 13G/A | Bios 2024 Co-Invest, LP | 0.72% | 562,695 | View |
| May 08, 2026 | SCHEDULE 13G | Lynwood Capital Management Inc. | 6.1% | 4,750,000 | View |
| May 08, 2026 | SCHEDULE 13G | Benjamin Shapiro | 6.1% | 4,750,000 | View |
| May 08, 2026 | SCHEDULE 13G | Lynwood Opportunities Master Fund | 6.1% | 4,750,000 | View |
| May 07, 2026 | SCHEDULE 13G | Funicular Funds, LP | 6.7% | 5,195,000 | View |
| May 07, 2026 | SCHEDULE 13G | Cable Car Capital, LP | 6.7% | 5,195,000 | View |
| May 07, 2026 | SCHEDULE 13G | Ma-Weaver Jacob | 6.7% | 5,195,000 | View |
| May 06, 2026 | SCHEDULE 13G | LYTTON LAURENCE W | 5.8% | 4,500,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Value Master Fund, LP | 3.5% | 926,441 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Value-Oriented Special Situations Fund, LP | 1.9% | 500,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Advisors GP, LLC | 5.4% | 1,426,441 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Voss Capital, LP | 17.0% | 4,468,969 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Cocke Travis W. | 17.0% | 4,468,969 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.